WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Vertex Makes A $10 Billion Deal; Biotech Stock Doubles — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 7 fonti

Vertex Makes A $10 Billion Deal; Biotech Stock Doubles

Crinetics stock nearly doubled Tuesday after Vertex pledged $10 billion to buy the endocrinology-focused biotech.

Raccontata da

markets.businessinsider.com

biopharmadive.com

fiercepharma.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo21 g fa

Vertex Makes A $10 Billion Deal; Biotech Stock Doubles

Crinetics stock nearly doubled Tuesday after Vertex pledged $10 billion to buy the endocrinology-focused biotech.

Timeline cronologica

lunedì 6 luglio 2026·markets.businessinsider.com
M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition
Vertex Pharmaceuticals (VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker Crinetics Pharmaceut...
lunedì 6 luglio 2026·endpoints.news
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and endocrinology pipeline with ~$5B peak sales potential.

markets.businessinsider.com

21 g fa

M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition

Vertex Pharmaceuticals (VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker Crinetics Pharmaceut...

Leggi questa versione → originale

biopharmadive.com20 g fa

Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.

Leggi questa versione → originale

statnews.com21 g fa

Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms

Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder, the companies announced.

Leggi questa versione → originale

endpoints.news21 g fa

Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics

Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and endocrinology pipeline with ~$5B peak sales potential.

Leggi questa versione → originale

benzinga.com20 g fa

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets - Vertex Pharmaceuticals (NASDAQ:V

Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to its rare disease portfolio.

Leggi questa versione → originale

lunedì 6 luglio 2026·

benzinga.com

Crinetics Pharmaceuticals Stock Doubles After The Close: Here's Why - Crinetics Pharmaceuticals (NASDAQ:C

Crinetics Pharmaceuticals shares are trading higher in Monday's after-hours session after the company announced it will be acquired by Vertex.

lunedì 6 luglio 2026·

investors.com

Vertex Makes A $10 Billion Deal; Biotech Stock Doubles

Crinetics stock nearly doubled Tuesday after Vertex pledged $10 billion to buy the endocrinology-focused biotech.

lunedì 6 luglio 2026·

statnews.com

Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms

Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder, the companies announced.

martedì 7 luglio 2026·

biopharmadive.com

Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.

martedì 7 luglio 2026·

benzinga.com

Why Crinetics Pharmaceuticals Shares Are Trading Higher By 99%; Here Are 20 Stocks Moving Premarket - Riv

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) rose in pre-market trading after being acquired by Vertex Pharmaceuticals (NASDAQ: VRTX) for $85/share.

martedì 7 luglio 2026·

fiercepharma.com

Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B

Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire | Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire endocrine…

martedì 7 luglio 2026·

benzinga.com

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets - Vertex Pharmaceuticals (NASDAQ:V

Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to its rare disease portfolio.

martedì 7 luglio 2026·

statnews.com

Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more

Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder

martedì 7 luglio 2026·

endpoints.news

Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks

By acquiring Crinetics Pharmaceuticals, Vertex is staking its place alongside other big biotechs such as Gilead, Regeneron and Biogen.